almitrine

Small moleculeexperimental

Almitrine is a diphenylmethylpiperazine derivative classified as a respiratory stimulant by the ATC. It enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep. A significant literature exists for this compound, including over 60 papers that Medline labels as reviews. — Wikipedia

Clinical trial activity

1 trials · 2 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started May 31, 2020 (NCT04357457)

Timeline

2020s

  1. Jan 1, 2020

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • Unspecified targetOTHER

    Unknown

    Almitrine is a respiratory stimulant that enhances respiration by acting as an agonist of peripheral chemoreceptors located on the carotid bodies. The drug increases arterial oxygen tension while decreasing arterial carbon dioxide tension in patients with chronic obstructive pulmonary disease. It may also prove useful in the treatment of nocturnal oxygen desaturation without impairing the quality of sleep.

Chemistry & pharmacology

Loading structure…

SMILES

C=CCNc1nc(NCC=C)nc(N2CCN(C(c3ccc(F)cc3)c3ccc(F)cc3)CC2)n1
Mol. weight
477.56 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2,4-bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine
  • 2,4-bis(allylamino)-6-(4-(bis(p-fluorophenyl)methyl)-1-piperazinyl)-s-triazine
  • almitrina
  • almitrina
  • almitrine
  • almitrine
  • almitrine
  • almitrine
  • almitrine
  • almitrine
  • almitrine
  • almitrine
  • almitrine dimesilate
  • almitrine mesilate
  • almitrinum
  • almitrinum
  • duxil

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT04357457Phase 3May 31, 2020Assistance Publique - Hôpitaux de Paris, Centre Hospitalier of Chartres
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (2)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Assistance Publique - Hôpitaux de ParisAcademic/Hospital1112020
Centre Hospitalier of ChartresAcademic/Hospital1012020
2 organizations
Page 1 / 1